The Anglo-Swedish pharmaceuticals group ASTRAZENECA has acquired the Belgian company BIO-THERABEL from the THERABEL group. The value of the transaction was not disclosed. Most of BIO-THERABEL's activity, employing 32, is essentially focused on sale and information to the medical corps concerning the product "Logastric" (a treatment against gastro-oesophagus reflow and ulcers), which generated a turnover of BF 914 million last year.